US FDA to convene expert panel for Capricor Therapeutics’ DMD cell therapy
By Siddhi Mahatole (Reuters) -Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company’s cell therapy for a heart condition related to Duchenne muscular dystrophy (DMD). Shares of the drug developer fell nearly 15% to $10.11 in morning trade. The …
US FDA to convene expert panel for Capricor Therapeutics’ DMD cell therapy Read More »









